Caredx Inc (CDNA) Stock Price, Quote & News

Company Profile

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offer...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 415 287 2300

Fax: 415 287 2450

Website: caredx.com

Address:

8000 Marina Boulevard, Brisbane, United States

SuperGreenToday May. 27 at 1:26 PM

$CDNA Share Price: $21.53 Contract Selected: Nov 20, 2026 $20 Calls Buy Zone: $4.35 – $5.37 Target Zone: $7.19 – $8.79 Potential Upside: 56% ROI Time to Expiration: 176 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

DavyDaveCharts May. 21 at 9:37 PM

$CDNA the set up is there, on this monthly chart, for a run to 35.

0 · Reply

BioTechHealthX May. 17 at 5:43 PM

$CDNA CareDx may not be a household biotech name, but its Q1 2026 results are hard to ignore. With revenue up 39%, testing services volume rising, and stronger guidance, CDNA could be one of the most interesting small-cap diagnostics stocks to watch. https://biotechhealthx.com/biotech-news/could-caredx-cdna-be-an-underrated-medical-testing-stock-with-upside/

0 · Reply

BioTechHealthX May. 17 at 10:49 AM

$CDNA $GRAL $NBIX $TNGX $VCYT For investors searching for the best biotech stocks to buy now, these 5 companies offer exposure to diagnostics, rare disease, cancer screening, RNA medicine, and commercial-stage biotech growth. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-that-could-climb-as-much-as-100/

0 · Reply

NVDAMillionaire May. 14 at 7:54 AM

$CDNA Really good write-up that perfectly summarizes CDNA's present situation. So if you want to bring your CDNA knowledge up to date or just discover CDNA, this is required reading. https://everyticker.com/quote/CDNA/analysis/caredx-s-platform-pivot-can-workflow-integration-save-the-transplant-surveillance-franchise-nasdaq-cdna

0 · Reply

BillionerOfKing May. 11 at 12:34 PM

$CDNA Current Stock Price: $21.84 Contracts to trade: $22.5 CDNA May 15 2026 Call Entry: $0.45 Exit: $0.89 ROI: 98% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Doozio May. 10 at 7:42 PM

$CDNA out of the tightness ONTO 🐒🍌🧠⏰♾️

0 · Reply

BioTechHealthX May. 10 at 5:17 PM

$CDNA CareDx is gaining attention as a precision medicine stock with strong transplant diagnostics growth, improving profitability, and a new AI-powered analytics platform. With revenue up 39% year over year and 2026 guidance raised, CDNA could be one of the more balanced biotech stocks to watch now. https://biotechhealthx.com/biotech-news/is-it-a-smart-move-to-buy-caredx-cdna-shares-today/

0 · Reply

BioTechHealthX May. 10 at 4:21 AM

$ARQT $CDNA $NBIX $VCYT $BHVN These top 5 biotech stocks to buy for May 2026 are not just random healthcare names. With projected EPS growth reaching up to 215%, rising sales expectations, precision medicine exposure, and high-risk, high-reward biotech potential, this list could grab serious investor attention. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-to-buy-with-up-to-215-projected-eps-growth/

0 · Reply

GoldenTicket1 May. 1 at 2:31 PM

$CDNA Up 11.67% since this post. Dont get scared off by manipulation. This will only continue to climb. They're a leader in their field.

0 · Reply

CareDx Transcript: Jefferies Global Healthcare Conference 2026

2026-06-01T16:20:10.000Z - 2 days ago

CareDx denied request to Supreme Court to revive Natera award

NTRA

May 20, 2026, 4:01 PM EDT - 14 days ago

CareDx to Participate in Upcoming Investor Conferences

2026-05-11T21:20:05.000Z - 23 days ago

CareDx announces dismissal of 2021 Qui Tam Suit

May 11, 2026, 4:05 PM EDT - 23 days ago

CareDx Announces Dismissal of 2021 Qui Tam Suit

May 1, 2026, 4:01 PM EDT - 4 weeks ago

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-04-29T12:58:15.000Z - 5 weeks ago

CareDx price target raised to $28 from $26 at BTIG

2026-04-28T21:55:37.000Z - 5 weeks ago

CareDx files automatic mixed securities shelf

2026-04-28T21:42:11.000Z - 5 weeks ago

CareDx to acquire Naveris for $160M up-front, $100M in revenue milestones

2026-04-28T21:39:50.000Z - 5 weeks ago

CareDx raises FY26 revenue view to $447M-$465M from $420M-$444M

Apr 28, 2026, 4:30 PM EDT - 5 weeks ago

CareDx Earnings Call Transcript: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 5 weeks ago

CareDx Earnings release: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 5 weeks ago

CareDx Quarterly report: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 5 weeks ago

CareDx Slides: Q1 2026

2026-04-28T20:16:32.000Z - 5 weeks ago

CareDx reports Q1 EPS 34c, consensus 13c

Apr 28, 2026, 4:05 PM EDT - 5 weeks ago

CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing

Apr 28, 2026, 4:01 PM EDT - 5 weeks ago

CareDx Announces First Quarter 2026 Financial Results

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

CareDx Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

CareDx Proxy statement: Proxy filing

Apr 21, 2026, 4:01 PM EDT - 6 weeks ago

CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual Meeting

2026-04-20T12:02:04.000Z - 6 weeks ago

CareDx introduces AlloSeq Nano at EFI 2026

2026-04-20T12:01:00.000Z - 6 weeks ago

CareDx expects EuroBio agreement to close by end of Q3

Apr 20, 2026, 7:05 AM EDT - 6 weeks ago

CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing

Apr 16, 2026, 2:00 AM EDT - 7 weeks ago

Eurobio scientific signs definitive agreement to acquire CareDx's transplant Lab Product division

2026-04-15T20:40:16.000Z - 7 weeks ago

CareDx up 20% at $21 after Q1 pre-announcement, Lab Products divestment

2026-04-15T20:36:54.000Z - 7 weeks ago

CareDx to divest Lab Products unit to EuroBio for $170M cash consideration

2026-04-15T20:36:28.000Z - 7 weeks ago

CareDx reports preliminary Q1 revenue roughly $118M, consensus $102.49M

Apr 15, 2026, 4:30 PM EDT - 7 weeks ago

CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results

Apr 14, 2026, 4:01 PM EDT - 7 weeks ago

CareDx to Report First Quarter 2026 Financial Results on April 28, 2026

2026-03-05T21:06:26.000Z - 3 months ago

CareDx announces launch of VANTx

Mar 5, 2026, 4:01 PM EST - 3 months ago

CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx's Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets

Mar 3, 2026, 10:25 AM EST - 3 months ago

CareDx Transcript: 47th Annual Raymond James Institutional Investor Conference

2026-02-26T01:20:13.000Z - 3 months ago

CareDx price target raised to $26 from $25 at BTIG

2026-02-24T22:25:34.000Z - 3 months ago

CareDx CFO Nathan Smith steps down, COO Keith Kennedy to succeed

Feb 24, 2026, 5:15 PM EST - 3 months ago

CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

Feb 24, 2026, 4:30 PM EST - 3 months ago

CareDx Earnings Call Transcript: Q4 2025

Feb 24, 2026, 4:30 PM EST - 3 months ago

CareDx Annual report: Q4 2025

Feb 24, 2026, 4:30 PM EST - 3 months ago

CareDx Earnings release: Q4 2025

Feb 24, 2026, 4:30 PM EST - 3 months ago

CareDx Slides: Q4 2025

2026-02-24T21:08:06.000Z - 3 months ago

CareDx reports Q4 adjusted EPS 12c, consensus 23c

2026-02-24T21:07:12.000Z - 3 months ago

CareDx sees FY26 revenue $420M-$440M, consensus $417.67M

Feb 24, 2026, 4:01 PM EST - 3 months ago

CareDx Announces Fourth Quarter and Full Year 2025 Financial Results

Feb 18, 2026, 8:00 AM EST - 3 months ago

CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference

Feb 12, 2026, 10:00 AM EST - 3 months ago

CareDx Transcript: Status update

Feb 12, 2026, 10:00 AM EST - 3 months ago

CareDx Press release: Status update

Feb 12, 2026, 10:00 AM EST - 3 months ago

CareDx Slides: Status update

Feb 12, 2026, 7:05 AM EST - 4 months ago

CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy

Feb 10, 2026, 4:01 PM EST - 4 months ago

CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Feb 3, 2026, 7:05 AM EST - 4 months ago

CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

Jan 27, 2026, 4:05 PM EST - 4 months ago

CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

2026-01-12T12:42:39.000Z - 5 months ago

CareDx reports preliminary Q4 revenue $108M, consensus $102.58M

Jan 12, 2026, 7:05 AM EST - 5 months ago

CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Jan 7, 2026, 7:05 AM EST - 5 months ago

CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

TXG

Dec 18, 2025, 5:00 PM EST - 5 months ago

CareDx Provides Notice of Proposed Derivative Settlement

Dec 3, 2025, 4:30 PM EST - 6 months ago

CareDx Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 4:05 PM EST - 6 months ago

SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation

Nov 20, 2025, 9:00 AM EST - 6 months ago

CareDx Transcript: Stephens Annual Investment Conference

Nov 6, 2025, 8:00 AM EST - 7 months ago

CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

CareDx Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

CareDx Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

CareDx Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

CareDx Slides: Q3 2025

Nov 4, 2025, 4:05 PM EST - 7 months ago

CareDx Announces Third Quarter 2025 Financial Results

Oct 27, 2025, 7:05 AM EDT - 7 months ago

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

Oct 23, 2025, 4:05 PM EDT - 7 months ago

CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure

Oct 22, 2025, 4:01 PM EDT - 8 months ago

CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors

Oct 21, 2025, 8:00 AM EDT - 8 months ago

CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 6, 2025, 7:05 AM EDT - 8 months ago

CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting

Sep 5, 2025, 8:00 AM EDT - 9 months ago

CareDx Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 4:01 PM EDT - 9 months ago

CareDx Issues Comment Letter on Draft LCD Policy

Aug 21, 2025, 4:01 PM EDT - 10 months ago

CareDx to Participate in Wells Fargo Healthcare Conference

Aug 6, 2025, 4:57 PM EDT - 10 months ago

CareDx Announces Appointment of Nathan Smith as Chief Financial Officer

Aug 6, 2025, 4:30 PM EDT - 10 months ago

CareDx Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

CareDx Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

CareDx Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

CareDx Slides: Q2 2025

Aug 6, 2025, 4:01 PM EDT - 10 months ago

CareDx Announces Second Quarter 2025 Financial Results

Aug 6, 2025, 12:56 PM EDT - 10 months ago

CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation

Jul 31, 2025, 4:01 PM EDT - 10 months ago

CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress

Jul 23, 2025, 7:05 AM EDT - 11 months ago

CareDx to Report Second Quarter 2025 Financial Results

Jul 18, 2025, 8:00 AM EDT - 11 months ago

CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection

Jun 9, 2025, 3:20 PM EDT - 1 year ago

CareDx Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 10:30 AM EDT - 1 year ago

CareDx Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 10:30 AM EDT - 1 year ago

CareDx Slides: FY 2025

Jun 3, 2025, 4:30 PM EDT - 1 year ago

CareDx Announces Repurchase of 5% of Outstanding Shares

Apr 30, 2025, 4:30 PM EDT - 1 year ago

CareDx Earnings Call Transcript: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

CareDx Quarterly report: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

CareDx Earnings release: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

CareDx Slides: Q1 2025

Apr 30, 2025, 4:05 PM EDT - 1 year ago

CareDx Reports First Quarter 2025 Results

Apr 29, 2025, 7:05 AM EDT - 1 year ago

CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting

Apr 28, 2025, 8:00 AM EDT - 1 year ago

CareDx Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

CareDx Proxy statement: Proxy Filing

Apr 24, 2025, 7:05 AM EDT - 1 year ago

CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting

Apr 21, 2025, 4:01 PM EDT - 1 year ago

CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Apr 8, 2025, 7:05 AM EDT - 1 year ago

CareDx to Report First Quarter 2025 Financial Results

Mar 28, 2025, 6:07 PM EDT - 1 year ago

CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

Mar 20, 2025, 7:00 AM EDT - 1 year ago

CI Global Asset Management Announces Securityholder Approval of Fund Mergers

Mar 14, 2025, 10:50 PM EDT - 1 year ago

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

Mar 11, 2025, 7:05 AM EDT - 1 year ago

CareDx Launches Two Expanded Indications for AlloSure Testing Services

Feb 26, 2025, 4:30 PM EST - 1 year ago

CareDx Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

CareDx Annual report: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

CareDx Earnings release: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

CareDx Slides: Q4 2024

Feb 26, 2025, 4:05 PM EST - 1 year ago

CareDx Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 7:05 AM EST - 1 year ago

CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict

Feb 20, 2025, 7:05 AM EST - 1 year ago

CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients

SuperGreenToday May. 27 at 1:26 PM

0 · Reply

DavyDaveCharts May. 21 at 9:37 PM

$CDNA the set up is there, on this monthly chart, for a run to 35.

0 · Reply

BioTechHealthX May. 17 at 5:43 PM

0 · Reply

BioTechHealthX May. 17 at 10:49 AM

0 · Reply

NVDAMillionaire May. 14 at 7:54 AM

0 · Reply

BillionerOfKing May. 11 at 12:34 PM

0 · Reply

Doozio May. 10 at 7:42 PM

$CDNA out of the tightness ONTO 🐒🍌🧠⏰♾️

0 · Reply

BioTechHealthX May. 10 at 5:17 PM

0 · Reply

BioTechHealthX May. 10 at 4:21 AM

0 · Reply

GoldenTicket1 May. 1 at 2:31 PM

$CDNA Up 11.67% since this post. Dont get scared off by manipulation. This will only continue to climb. They're a leader in their field.

0 · Reply

Bazzzigar Apr. 30 at 7:47 PM

$CDNA join with ABT

0 · Reply

GoldenTicket1 Apr. 29 at 6:34 PM

$CDNA Another ridiculous reaction. This will be back at $22 in a week or two. Bookmark it.

0 · Reply

Bazzzigar Apr. 29 at 5:57 PM

$CDNA

0 · Reply

RazorbackAJ Apr. 29 at 5:35 PM

$CDNA Down 13%+ from this call and stop moved to $19.5 and in deep profit! Follow so you don't miss the next one — exact entry, exact stop, no fluff.

0 · Reply

OpenOutcrier Apr. 29 at 1:00 PM

$CDNA (-5.3% pre) CareDx (CDNA) files mixed shelf https://ooc.bz/l/100441

0 · Reply

DARKP00L Apr. 29 at 11:34 AM

$CDNA 07:27 on Apr. 29 2026 BTIG Maintains Buy on CareDx, Raises Price Target to $28 #tradeideas

0 · Reply

Olivia_Strickland Apr. 28 at 9:14 PM

$CDNA -5.25% AH to 20.76 on the Q1 print plus the Naveris acquisition announcement, tape reading the cancer MRD bolt-on as dilutive optics rather than a strategic win. $1.1B cap giving back some of the +17.8% monthly run, gonna see if 20 Source: https://tapeboard.com/chart/CDNA

0 · Reply

RazorbackAJ Apr. 28 at 9:04 PM

$CDNA Could be a great risk/reward short here into tomorrow with current trailing stop at $22.55. Follow for setups like this — exact entries, precise stop levels, nothing vague. This is how I trade, not financial advice.

1 · Reply

Bogwood Apr. 28 at 8:24 PM

$IMDX Look at this pivot guys!!!! Incumbant $CDNA CareDx last week sold off their HLA/ddcf-DNA kit biz, and then used that cash to buy another MRD/cancer diag biz. They've all but folded their transplant hand accepting they're checkmated when it comes to GraftAssure in '27 https://investors.caredx.com/news/news-details/2026/CareDx-Announces-Agreement-to-Acquire-Naveris-A-Leader-in-Viral-Mediated-Cancer-MRD-Surveillance-Testing/default.aspx

0 · Reply

d_risk Apr. 28 at 8:21 PM

$CDNA - CareDx Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +135.5% above peer average (28,434 vs 12,075 across 652 peers). CDNA’s 10-Q adds a wall of new risks: sustained losses and dependence on Medicare and a handful of transplant tests, heavy reliance on third parties and a single U.S. lab, intense tech and IP pressure in transplant diagnostics, plus elevated stock, governance and capital-raising risks that could constrain growth and amplify volatility. 🟢 Added 🟠 Removed https://d-risk.ai/CDNA/10-Q/2026-04-28

0 · Reply

StocktwitsEarnings Apr. 28 at 8:11 PM

$CDNA Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.05 up 126.32% YoY • Reported revenue of $117.7M up 38.99% YoY • CareDx raised its full year 2026 revenue guidance to $447 million to $465 million, and adjusted EBITDA guidance to $43 million to $57 million, reflecting an improved outlook for the company.

0 · Reply

11thestate Apr. 28 at 4:50 PM

Missed the CareDx ($CDNA) deadline? You can still file Most investors assume they're out of luck once the date passes, but the $20.25 million CareDx settlement is currently accepting "Late-but-Valid" claims. If you bought shares between April 30, 2020, and November 3, 2022, you still have a chance to seek recovery. Submit your late claim here: https://11th.com/cases/caredx-investor-settlement This recovery fund was established after claims that CareDx misled information about revenue quality and compliance with Medicare billing rules. Even though the official deadline has passed, the court is still accepting late submissions.

0 · Reply

Market Cap	1.14B
Revenue (ttm)	379.81M
Net Income (ttm)	-21.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	103.64
Profit Margin	-5.62%
Debt to Equity Ratio	0.00

Volume	700,200
Avg Vol	724,564
Day's Range	N/A - N/A
Shares Out	51.66M
Stochastic %K	92%
Beta	2.49
Analysts	Sell
Price Target	$25.80